Clinical Trials Directory

Trials / Completed

CompletedNCT06660849

Atrial Fibrillation Duration and Cortical Lens Opacity

Predicting the Presence and Duration of Atrial Fibrillation From Cortical Lens Opacity

Status
Completed
Phase
Study type
Observational
Enrollment
400 (actual)
Sponsor
Ankara Ataturk Sanatorium Training and Research Hospital · Other Government
Sex
All
Age
60 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The prevalence of atrial fibrillation (AF) and the risk of stroke increase with a higher CHA2DS2-VASc score. Osmotic stress, which also contributes to cortical cataract formation, increases in the presence of diseases that raise the CHA2DS2-VASc score. Knowledge of AF duration is crucial because it heightens the risk of AF-related complications. This study investigated whether the presence of cortical cataracts, classified using the Lens Opacity Classification System (LOCS)stage, can predict the presence and duration of AF.

Detailed description

Atrial fibrillation (AF) is the most common type of heart rhythm disorder encountered in clinical settings and is associated with increased morbidity and mortality. The prevalence of AF and the risk of stroke increase with higher CHA2DS2-VASc scores . Cortical cataracts develop at the periphery of the lens and progress toward the center in a spoke-like pattern. The incidences of AF and cortical cataracts significantly increase with age . Similar to subclinical AF, the initial onset of AF may go undetected, and the time required for AF to become permanent varies. Longer episodes of AF and higher CHA2DS2-VASc scores are strongly associated with an increased annual risk of stroke or systemic embolism , making it essential to estimate the duration of AF. Cortical cataract stages can be easily identified and monitored through simple biomicroscopic examination. To our knowledge, no reliable method currently exists to predict the duration of AF of unknown onset. This study investigated the relationship between cortical cataract stages and the presence and duration of AF by analyzing p.osmolarity data and comparing it with the LAVI.

Conditions

Timeline

Start date
2017-07-01
Primary completion
2024-03-01
Completion
2024-06-01
First posted
2024-10-28
Last updated
2024-10-28

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06660849. Inclusion in this directory is not an endorsement.